An interventional study of Oxygen therapy delivery systems in Acute Respiratory Failure, sponsored by Nantes University Hospital. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-07.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Treatment
The main objective of this study is to evaluate the efficiency of the oxygen therapy delivery system Optiflow® compared to 2 others standard oxygen therapy delivery systems (Ospal®, non invasive ventilation).12 immunocompetent patients will compare the successive use of oxygen therapy delivery systems Optiflow®/Ospal® and 12 immunodeficient patients will compare the successive use of systems Optiflow®/Non invasive ventilation.
1,650 studies on the registry are indexed under Respiratory Insufficiency; 296 are open to participants now.
This study's enrollment of 16 is below the median of 55 across 1,043 interventional studies indexed under Respiratory Insufficiency.
Browse Respiratory Insufficiency studies →Nantes University Hospital is the lead sponsor of 825 studies on the registry; 195 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
VNI = non invasive ventilation
Other: Oxygen therapy delivery systems
VNI = non invasive ventilation
Other: Oxygen therapy delivery systems
Other: Oxygen therapy delivery systems
Other: Oxygen therapy delivery systems
T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
Calcul of the ratio PaO2/FiO2
The main objective of this study is to evaluate the efficiency of the oxygen therapy delivery system Optiflow® compared to 2 others standard oxygen therapy delivery systems (Ospal®, non invasive ventilation) by calculating the ratio PaO2/FiO2
Time frame: one hour after each system used
number of participants with adverse events
The secondary outcomes are to understand the mechanisms of action of Optiflow system and to evaluate the tolerance of this system: * number of adverse events: respiratory events, trophic troubles, subjective events (comfort, dryness of mucous membranes, gastric distension, preferred system), serious hemodynamic and cardiovascular events * impact on work of breathing: measure of respiratory frequency and blood gas * measure of positive and expiratory pressure
measure of respiratory frequency and blood gas
The secondary outcomes are to understand the mechanisms of action of Optiflow system and to evaluate the tolerance of this system: * number of adverse events: respiratory events, trophic troubles, subjective events (comfort, dryness of mucous membranes, gastric distension, preferred system), serious hemodynamic and cardiovascular events * impact on work of breathing: measure of respiratory frequency and blood gas * measure of positive and expiratory pressure
measure of positive and expiratory pressure
The secondary outcomes are to understand the mechanisms of action of Optiflow system and to evaluate the tolerance of this system: * number of adverse events: respiratory events, trophic troubles, subjective events (comfort, dryness of mucous membranes, gastric distension, preferred system), serious hemodynamic and cardiovascular events * impact on work of breathing: measure of respiratory frequency and blood gas * measure of positive and expiratory pressure
This study is terminated, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nantes University Hospital